NFKBIA Antibodies

NF-kappa-B inhibitor alpha (NFKBIA)

Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers from the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by resistant and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate into the nucleus and activate transcription.

.

Gene Information

Human
Gene Name:	NFKBIA
Uniprot:	P25963
Entrez:	4792

Family

Belongs to:
NF-kappa-B inhibitor family

Alternative Names

alpha; I-kappa-B-alpha; IkappaBalphaNF-kappa-B inhibitor alpha; IKBAikB-alpha; IkBalpha; IkB-alpha; MAD3; MAD-3; Major histocompatibility complex enhancer-binding protein MAD3; NFKBI; NFKBIA; nuclear factor of kappa light chain gene enhancer in B-cells; nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor

Molecular Weight

Mass (kDA):
35.609 kDA

Genomic Context

Human
Location:	14q13.2
Sequence:	14; NC_000014.9 (35401513..35404749, complement)

Subcellular Localizations

Cytoplasm. Nucleus. Shuttles between the nucleus and the cytoplasm by a nuclear localization signal (NLS) and a CRM1-dependent nuclear export.

Diseases

• Neoplasms
• Malignant Neoplasms
• Inflammation
• Inflammatory Response
• Lymphoma
• Malignant Paraganglionic Neoplasm
• Hodgkin Disease
• Carcinoma
• Tissue Adhesions
• Innate Immune Response
• Neoplasm Metastasis
• Autoimmune Diseases
• Crohn Disease

• Autoimmune Reaction
• Glioblastoma
• Dysequilibrium Syndrome
• Infective Disorder
• Malignant Neoplasm Of Breast
• Cell Transformation, Neoplastic
• Cholangiocarcinoma

Interacting Proteins

• CHUK
• COMMD1
• CTNNA1
• FBXW11
• GRK2

• GRK5
• HIF1AN
• IKBKB
• IKBKG
• NEDD9

• NFKB1
• NFKB2
• REL
• RELA
• RPS3

• UBC

Pathways

• Immune Response
• Inflammatory Response
• Pathogenesis
• Cell Proliferation
• Translation
• Innate Immune Response
• Cell Death
• Cell Cycle
• Cytokine Production
• Localization
• Methylation
• Rna Interference
• Secretion

• Response To Lipopolysaccharide
• Cell Adhesion
• Cell Migration
• Programmed Cell Death
• Gene Silencing
• Aging
• Regulation Of Gene Expression

PTMs

• Phosphorylation
• Biotinylation

• Acetylation
• Methylation

Research Areas

• Apoptosis
• Chaperone-Mediated Autophagy (CMA)
• Diabetes Research

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/NFKBIA

Best Uses Of The NFKBIA Marker By Boster Bio

The nuclear factor 1A-type antibodies are a powerful and important tool for research. These antibodies detect levels this protein in a variety animal samples. Boster Bio has developed Nuclear factor 1A-type antibodies using rabbits as well as mice. Nuclear factor 1A-type proteins activate transcription, and replication. Antibodies that detect this protein in a variety of samples include human blood, urine, and other biological fluids.

NFKBIA Marker

RNA-seq (or smRNA–FISH) provide single-cell expression for CD83 and NFKBIA, respectively. These markers can be used to identify tumor microenvironment clusters of activated cell clusters at low levels. They are also correlated at low levels. This analysis can help determine if cells are sensitive to certain chemotherapeutics agents and whether or not they express NFKBIA, CD83.

The NFKBIA genes encode the alpha subunit for the IKK protein complex. It regulates the nuclear factor kappa b's activity. This protein binds and regulates multiple genes. It may also play a role the development of ectodermal tissues. It is a candidate gene for several diseases, including cancer.

NFKBIA can be used to determine whether CD83 and NFKBIA are present. It also has potential biological functions. For instance, this gene may promote the secretion of cytokines in cells and regulates the inflammatory response. Its expression pattern can be misleading. It has been demonstrated to be highly variable when used in non-cooperative settings. Bimodality has been observed in CD83 mRNAs and NFKBIA mRNAs. They have varying sensitivities for JQ1 and IL-17.

Nuclear factor 1 A-type antibodies

Boster bio Nuclear factor 1 A type antibody is an option if you are looking for a nuclear-type A-type anti-body that reacts with human and mouse samples. This antibody is tested in flow cytometry, immunocytochemistry (IHC), and Western blotting. The antibody binds with human NFIA (180-224).

Boster Bio's nuclear factor-A-type antibody range consists a range recombinant antibodies and a wide variety of ELISA kits. The company is committed in developing high-sensitivity ELISA kits and research antibody that can detect biomarkers within human samples. Its quality assurance program includes a guarantee that your research will not be interrupted. Boster Quality Guarantee provides another benefit.

After determining the reagents used, samples were prepared to be used in western blotting. The samples were then loaded onto polyacrylamide Gels and incubated using primary antibodies against RANKL/RUNX2. The primary antibodies were first added at 4°C overnight, then followed by secondary antibodies for 2 hours at ambient temperature. After incubation was complete, samples were exposed for image analysis or development in a darkened room. Finally, relative proteins were calculated using GAPDH to determine their expression.

NFKBIA marker in RNA–Seq

To detect NFKBIA gene activity by RNA–Seq, 377 patients with gastric cancer were downloaded bulk RNA–seq data using the TCGA Biolinks package. GeoTcgaData used the GeoTcgaData to normalize the count data for transcripts/million. Additional data included clinical and immune cell fraction data as well as gene expression levels.

Seurat 3.1 was used to normalize and cluster the raw data. It allows for differential gene expression analyses, visualization, as well as detection of cell cluster markers genes. In the present study, the average expression of a cluster was compared to the expression levels of all other cells. Bonferroni-corrected values of p were used for statistically significant DEGs. We selected genes with a fold difference greater than 2fold.

NFKBIA marker in ELISA

NFKBIA, a protein found in all cells of our bodies, is a protein. It is a protooncogene. NFkB contains 551 amino acid residues and a weight of 60.219 daltons. NFkB ELISA kits can be used in mammalian, poultry, and bovine cells.

The NFKBIA genome provides instructions for the production of the alpha subunit (or IKK protein complex) of the IKK family of proteins. The IKK Complex regulates the activity nuclear factor-kappaB, which binds DNA and controls the expression other genes. When activated the nuclear factor-kappa binds to IKK. The ELISA marker NFKBIA may indicate whether EGFR proteins are present in human cells.

NFKBIA p65 ELISA is designed for the semi-quantitative measurement of human NFkB p65 protein. It can also detect NFkB in mice and rats. It has the advantage that it allows rapid analysis of samples in less time than an hour. The sandwich ELISA technique uses reagents mixed in solution. This is followed by a wash and detection using TMB colorimetric substrate.

NFKBIA mediated cytokine response was associated transcriptomic changes NG and IUGR neonates. IP LPS did not induce robust acute hepatic-proinflammatory gene expression in NG or IUGR neonates. This finding suggests that therapeutic treatments that target NFkB may be successful in treating neonatal sepsis.

Boster Bio has created nuclear factor A-type antibodies

Boster Bio developed the Nuclear factor 1A-type antibody. It reacts with IL-1 Beta proteins from rat, mouse, and human. This antibody shares 78.3% identity with rat and mouse IL-1 beta proteins. Its versatility makes it an invaluable tool for analyzing and interpreting the effects of various activators and treatments. The ELISA kits of the ELISA kit can be used in a variety if settings to screen the effects on different treatments.

SeroNet is researching the effects of vaccines on different types of treatment. These studies will focus upon the role that the immune system plays in vaccination. The antibody works by identifying circulating IL-1B mRNA. It is present in a wide range of cancers, viruses, and other diseases. SeroNet is currently conducting clinical research and testing a new vaccine for COVID-19.